Pneumologie 2024; 78(S 01): S9
DOI: 10.1055/s-0044-1778750
Abstracts
Asthma, Allergologie und Immunologie

The German Asthma Net: FeNO dynamics mark long-term asthma burden and lung function changes

Authors

  • C Bal

    1   Division of Pulmonology, Department of Internal Medicine II, Medical University Vienna, Austria

  • K Milger-Kneidinger

    2   Department of Medicine V, LMU University Hospital Munich; Comprehensive Pneumology Center (Cpc-M), Member of the German Center for Lung Research (Dzl); Medizinische Klinik V

  • D Skowasch

    3   Uniklinikum Bonn; Medizinische Klinik Ii; Kardiologie, Pneumologie

  • C Schulz

    4   Klinik und Poliklinik für Innere Medizin Ii; Pneumologie; Department of Internal Medicine II, University Hospital Regensburg, Regensburg

  • M Jandl

    5   Asklepios-Klinik St. Georg; Hamburger Institut für Therapieforschung GmbH

  • O Schmidt

    6   Kppk GmbH, Koblenz, Germany; Pneumologische Facharztpraxis, Koblenz

  • R Ehmann

    7   Ambulante Pneumologie Mit Allergiezentrum (Bag)

  • S Stoshikj

    8   Akh Wien

  • C Taube

    9   Universitätsklinikum Essen – Ruhrlandklinik; Klinik für Pneumologie

  • E Hamelmann

    10   Klinik für Kinder- und Jugendmedizin Bielefeld; Universitätsklinikum Owl, Universität Bielefeld; Kinderzentrum Bethel, Evangelisches Klinikum Bethel, University Bielefeld, Bielefeld

  • R Buhl

    11   Universität Mainz; Med. Klinik; Schwerpunkt Pneumologie, III.

  • S Korn

    12   Ikf Pneumologie Mainz; Thoraxklinik Heidelberg, Universitätsklinikum Heidelberg, Heidelberg, Deutschland und Ikf Pneumologie Mainz, Mainz, Deutschland; Clinical Research Centre Respiratory Diseases

  • M Idzko

    13   Universitätsklinik für Innere Medizin Ii; Abteilung für Pulmonologie; Ebene 6/L
Further Information
Also available at
 
 

    The fraction of exhaled nitric oxide (FeNO) is a biomarker for type 2 inflammation in asthma, but the significance of long-term FeNO changes on relevant parameters is unclear.

    This longitudinal study assesses FeNO differences at a follow-up of (mean±SD) 16.2±15.1 months in 526 patients of the German Asthma Net (GAN), an international, multi-centre, and real-life registry of patients with severe asthma, through Kruskal-Wallis tests.

    Patients who showed any FeNO reductions had a significant reduction in their yearly exacerbation rate and maintenance corticosteroid use (OCS), clinically significant improvements in asthma control and quality of life, and significantly improved FEV1 in% predicted compared to patients with a FeNO increase (all p < 0.05). Patients with a FeNO reduction of more than 25 ppb at follow-up improved their FEV1 by 14% predicted in the mean. The rate of treatment with biologics was similar between groups ([Abb. 1]).

    Zoom
    Abb. 1

    In conclusion, we could show that long-term FeNO level reductions mark significant and clinically relevant improvements in vital parameters of disease burden, underscoring its relevance in assessing the underlying type 2 inflammation in patients with severe asthma.


     

    Publication History

    Article published online:
    01 March 2024

    © 2024. Thieme. All rights reserved.

    Georg Thieme Verlag
    Rüdigerstraße 14, 70469 Stuttgart, Germany

     
    Zoom
    Abb. 1